|
humans |
41 |
|
lung cancer |
38 |
|
female |
36 |
|
male |
36 |
|
bronchiectasis |
27 |
|
adult |
26 |
|
middle aged |
26 |
|
chronic obstructive pulmonary disease |
25 |
|
medical sciences |
24 |
|
aged |
21 |
|
covid-19 |
21 |
|
aged, 80 and over |
15 |
|
asthma |
15 |
|
aerobic exercise |
13 |
|
copd |
12 |
|
chemotherapy |
11 |
|
extracellular vesicles |
11 |
|
hepatocellular carcinoma |
11 |
|
nidogen 1 |
11 |
|
non-small cell lung cancer |
11 |
|
pre‐metastatic niche |
11 |
|
prospective studies |
11 |
|
tumor necrosis factor receptor 1 |
11 |
|
alanine transaminase - blood |
10 |
|
case-control studies |
10 |
|
chronic kidney disease |
10 |
|
hospitalization |
10 |
|
lung - radiography |
10 |
|
lung adenocarcinoma |
10 |
|
pneumonia |
10 |
|
disease progression |
9 |
|
epidemiology |
9 |
|
mortality |
9 |
|
respiratory diseases |
9 |
|
risk assessment |
9 |
|
severe acute respiratory syndrome |
9 |
|
survival |
9 |
|
tomography, x-ray computed |
9 |
|
treatment outcome |
9 |
|
adrenomedullin - genetics - metabolism |
8 |
|
biological markers - blood |
8 |
|
bronchiectasis exacerbation |
8 |
|
calcitonin receptor-like protein |
8 |
|
cell communication - physiology |
8 |
|
cell line |
8 |
|
cilia - metabolism - physiology |
8 |
|
eosinophil |
8 |
|
epidermal growth factor receptor |
8 |
|
epithelium - metabolism - physiology |
8 |
|
fallopian tubes - metabolism |
8 |
|
gene expression regulation - drug effects |
8 |
|
hormones - metabolism - pharmacology |
8 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
8 |
|
logistic models |
8 |
|
membrane proteins - genetics - metabolism |
8 |
|
menstrual cycle - genetics - metabolism - physiology |
8 |
|
models, biological |
8 |
|
pemetrexed |
8 |
|
phenotype |
8 |
|
probability |
8 |
|
prognosis |
8 |
|
pseudomonas aeruginosa |
8 |
|
receptor activity-modifying proteins |
8 |
|
receptors, calcitonin - genetics - metabolism |
8 |
|
spermatozoa - metabolism - physiology |
8 |
|
adrenomedullin |
7 |
|
advanced lung cancer |
7 |
|
cilia |
7 |
|
ciliary beat frequency |
7 |
|
cognitive function |
7 |
|
diagnosis |
7 |
|
drug repositioning |
7 |
|
dyspnea |
7 |
|
hong kong |
7 |
|
hong kong - epidemiology |
7 |
|
ischemic heart disease |
7 |
|
lung neoplasms - drug therapy |
7 |
|
lymphoepithelioma-like carcinoma |
7 |
|
metabolic re-programming |
7 |
|
molnupiravir |
7 |
|
nasal ciliated epithelium |
7 |
|
randomized controlled trial |
7 |
|
retrospective studies |
7 |
|
spirometry |
7 |
|
tai chi |
7 |
|
transmission electronic microscopy |
7 |
|
treatment |
7 |
|
trimetazidine |
7 |
|
tubal ectopic pregnancy |
7 |
|
tuberculosis |
7 |
|
vital capacity |
7 |
|
advanced cancer |
6 |
|
anaplastic lymphoma kinase |
6 |
|
anti-inflammatory agents - pharmacology |
6 |
|
aquaporin-5 |
6 |
|
asthma control |
6 |
|
bronchiectasis - metabolism |
6 |
|
carcinoma, non-small-cell lung - drug therapy |
6 |
|
cells, cultured |
6 |
|
ciliary central microtubular orientation |
6 |
|
cohort studies |
6 |
|
coronavirus disease 2019 |
6 |
|
corticosteroid |
6 |
|
dendrobium officinale polysaccharides |
6 |
|
dialysis |
6 |
|
diet therapy |
6 |
|
drug modulation |
6 |
|
epithelial cells |
6 |
|
forced expiratory volume - physiology |
6 |
|
gefitinib |
6 |
|
influenza |
6 |
|
interleukin-6 |
6 |
|
interleukin-6 - biosynthesis |
6 |
|
masks |
6 |
|
mucin-5ac |
6 |
|
respiratory failure |
6 |
|
ribavirin - therapeutic use |
6 |
|
secondary bacterial pneumonia |
6 |
|
severity of illness index |
6 |
|
tai-chi |
6 |
|
acute exacerbation |
5 |
|
acute exacerbation of chronic obstructive pulmonary disease |
5 |
|
acute kidney injury |
5 |
|
administration, inhalation |
5 |
|
adolescent |
5 |
|
alzheimer's disease |
5 |
|
amiodarone - adverse effects - analogs and derivatives |
5 |
|
androstadienes - administration & dosage |
5 |
|
anti-inflammatory agents - administration & dosage |
5 |
|
antibiotic agent |
5 |
|
antigens, cd56 - biosynthesis |
5 |
|
antiviral agents - therapeutic use |
5 |
|
apoptosis - drug effects |
5 |
|
aquaporin 5 |
5 |
|
asian continental ancestry group - genetics |
5 |
|
asthma exacerbation |
5 |
|
beta-amyloid |
5 |
|
blood cell count |
5 |
|
bronchiectasis - drug therapy |
5 |
|
carcinoma, non-small-cell lung - blood - genetics - pathology |
5 |
|
carcinoma, non-small-cell lung - enzymology - genetics - pathology |
5 |
|
carcinoma, squamous cell - diagnosis - therapy - ultrasonography |
5 |
|
cardiovascular disease |
5 |
|
cell line, tumor |
5 |
|
cell movement - drug effects |
5 |
|
cilia - physiology - ultrastructure |
5 |
|
coronavirus infection |
5 |
|
dna, neoplasm - blood - genetics |
5 |
|
dronedarone |
5 |
|
egfr array |
5 |
|
electrolyte |
5 |
|
endobronchial ultrasound |
5 |
|
eosinophilic phenotype |
5 |
|
fatal outcome |
5 |
|
follow-up |
5 |
|
gene amplification |
5 |
|
genotype |
5 |
|
hilar lymphadenopathy |
5 |
|
hyponatraemia |
5 |
|
immunohistochemistry |
5 |
|
incidence |
5 |
|
interstitial lung disease |
5 |
|
kidney function tests |
5 |
|
liver diseases - diagnosis - etiology |
5 |
|
lung diseases - chemically induced |
5 |
|
lung neoplasms - diagnosis - therapy - ultrasonography |
5 |
|
lung neoplasms - enzymology - genetics - pathology |
5 |
|
lymph node metastatic carcinoma |
5 |
|
lymph nodes - pathology |
5 |
|
metastasis |
5 |
|
methylprednisolone |
5 |
|
methylprednisolone - administration & dosage |
5 |
|
mutation |
5 |
|
mutation - genetics |
5 |
|
neoplasm invasiveness |
5 |
|
nirmatrelvir-ritonavir |
5 |
|
nirmatrelvir–ritonavir |
5 |
|
non-small-cell lung cancer |
5 |
|
phosphorylation - drug effects |
5 |
|
plasma egfr mutations |
5 |
|
polymorphism, genetic |
5 |
|
predictive value of tests |
5 |
|
primary carcinoma |
5 |
|
protein kinase inhibitors - pharmacology |
5 |
|
pulse therapy, drug - methods |
5 |
|
quinazolines - pharmacology |
5 |
|
receptor, epidermal growth factor - antagonists & inhibitors - genetics - metabolism |
5 |
|
receptor, epidermal growth factor - genetics |
5 |
|
reproducibility of results |
5 |
|
ribavirin |
5 |
|
rna, small interfering - genetics - metabolism |
5 |
|
sars-cov-2 |
5 |
|
severe acute respiratory syndrome - blood - complications - radiography |
5 |
|
severe acute respiratory syndrome - complications - diagnosis - metabolism |
5 |
|
severe acute respiratory syndrome - drug therapy |
5 |
|
small cell carcinoma |
5 |
|
sodium |
5 |
|
squamous cell carcinoma |
5 |
|
src-family kinases - antagonists & inhibitors - metabolism |
5 |
|
synchronous primary lung cancer |
5 |
|
therapeutic potential |
5 |
|
traditional chinese medicine |
5 |
|
transbronchial needle aspiration |
5 |
|
tumor markers, biological - blood - genetics |
5 |
|
tyrosine kinase inhibitor therapy |
5 |
|
ultrasonography - methods |
5 |
|
vaccine |
5 |
|
viral load |
5 |
|
α-secretases |
5 |
|
β-secretases |
5 |
|
antineoplastic agents - therapeutic use |
4 |
|
antioxidants - analysis - metabolism |
4 |
|
arsenic trioxide |
4 |
|
asian continental ancestry group |
4 |
|
aspartate aminotransferases - blood |
4 |
|
bacterial adherence |
4 |
|
bacterial adhesion - drug effects |
4 |
|
bacterial morphology |
4 |
|
biological availability |
4 |
|
biomarkers |
4 |
|
body temperature |
4 |
|
carcinoma, non-small-cell lung - enzymology - etiology - pathology |
4 |
|
carotid initial thickness |
4 |
|
catalase |
4 |
|
catalase - analysis - metabolism |
4 |
|
cell transformation, neoplastic - metabolism |
4 |
|
child |
4 |
|
collagen - physiology |
4 |
|
colonization |
4 |
|
coriolus versicolor |
4 |
|
culture media, conditioned |
4 |
|
cytokines |
4 |
|
deep learning |
4 |
|
dose-response relationship, drug |
4 |
|
double-blind method |
4 |
|
egfr |
4 |
|
egfr mutation |
4 |
|
egfr-tki |
4 |
|
epithelial–mesenchymal transition |
4 |
|
erlotinib |
4 |
|
erythrocytes - enzymology |
4 |
|
erythromycin |
4 |
|
erythromycin - pharmacology |
4 |
|
exacerbation |
4 |
|
feno |
4 |
|
fev1 |
4 |
|
gastric-acid suppressing agents |
4 |
|
gemcitabine |
4 |
|
genetics |
4 |
|
glutathione peroxidase |
4 |
|
glutathione peroxidase - analysis - metabolism |
4 |
|
heart rate |
4 |
|
hematological toxicity |
4 |
|
imaging cytometry |
4 |
|
inhaled corticosteroid |
4 |
|
interleukin-1beta (il-1β) |
4 |
|
interleukin-8 (il-8) |
4 |
|
label-free |
4 |
|
longitudinal studies |
4 |
|
low risk |
4 |
|
lung neoplasms - enzymology - etiology - pathology |
4 |
|
lung, infection |
4 |
|
maintenance chemotherapy |
4 |
|
microscopy, electron, scanning |
4 |
|
microscopy, electron, transmission |
4 |
|
neoplasm staging |
4 |
|
nephrotoxicity |
4 |
|
neutrophil to lymphocyte ratio |
4 |
|
non-cystic fibrosis bronchiectasis |
4 |
|
nsclc |
4 |
|
osimertinib |
4 |
|
oxidoreductases - analysis - metabolism |
4 |
|
oxygen - blood |
4 |
|
palliative treatment |
4 |
|
pilot projects |
4 |
|
plasma dna |
4 |
|
polysaccharide peptides (psp) |
4 |
|
proteoglycans - therapeutic use |
4 |
|
pseudomonas aeruginosa - drug effects - physiology |
4 |
|
quantitative phase imaging |
4 |
|
radiography, thoracic |
4 |
|
respiratory function tests |
4 |
|
salvage therapy |
4 |
|
second line chemotherapy |
4 |
|
sensitivity and specificity |
4 |
|
severe acute respiratory syndrome (sars) |
4 |
|
severe acute respiratory syndrome - diagnosis - radiography - therapy |
4 |
|
sputum |
4 |
|
sputum cytokines |
4 |
|
stage i non-small cell carcinoma of lung |
4 |
|
standardized uptake value |
4 |
|
statistics, nonparametric |
4 |
|
subclinical atherosclerosis |
4 |
|
subminimal inhibitory concentration |
4 |
|
superoxide dismutase |
4 |
|
superoxide dismutase - analysis - metabolism |
4 |
|
survival outcomes |
4 |
|
systemic immune-inflammation index (sii) |
4 |
|
targeted therapy |
4 |
|
tomography, x-ray computed - methods |
4 |
|
tumor necrosis factor-alpha (tnf-α) |
4 |
|
tyrosine kinase inhibitor |
4 |
|
18f-fdg pet/ct |
3 |
|
18f-fdg positron emission tomography |
3 |
|
5-fluorouracil |
3 |
|
adenocarcinoma |
3 |
|
adenocarcinoma - complications - diagnosis - ethnology |
3 |
|
adenocarcinoma - ethnology - genetics |
3 |
|
adhesion molecules |
3 |
|
adrenal cortex hormones - therapeutic use |
3 |
|
alectinib |
3 |
|
amino acid substitution |
3 |
|
anti-bacterial agents |
3 |
|
antineoplastic agents - adverse effects |
3 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
3 |
|
antioxidants |
3 |
|
arsenicals - adverse effects |
3 |
|
atrioventricular block |
3 |
|
biomarker |
3 |
|
bleeding |
3 |
|
bone marrow transplantation |
3 |
|
bone marrow transplantation - immunology |
3 |
|
brain metastasis |
3 |
|
breast carcinoma |
3 |
|
bronchiectasis - blood - physiopathology |
3 |
|
bronchiectasis - pathology |
3 |
|
bronchiectasis - pathology - radiography |
3 |
|
capecitabine |
3 |
|
carbohydrates |
3 |
|
carcinoma - etiology |
3 |
|
carcinoma - pathology - radiography - virology |
3 |
|
carcinoma of lung |
3 |
|
carcinoma, large cell - complications - diagnosis - ethnology |
3 |
|
carcinoma, non-small-cell lung - drug therapy - pathology - radiotherapy |
3 |
|
carcinoma, non-small-cell lung - pathology - radiography |
3 |
|
carcinoma, squamous cell - complications - diagnosis - ethnology |
3 |
|
cardiac magnetic resonance imaging |
3 |
|
cardiac patient |
3 |
|
case report |
3 |
|
catalase - genetics - metabolism |
3 |
|
child, preschool |
3 |
|
cilia - ultrastructure |
3 |
|
clara cell protein |
3 |
|
clinical presentation |
3 |
|
clinical profiles |
3 |
|
clinical trial |
3 |
|
competing risk analysis |
3 |
|
computed tomography |
3 |
|
confidence intervals |
3 |
|
conscious sedation |
3 |
|
corticosteroids |
3 |
|
cryptococcosis - diagnosis - epidemiology |
3 |
|
cryptococcus neoformans |
3 |
|
cysts |
3 |
|
deoxycytidine - analogs & derivatives - therapeutic use |
3 |
|
diagnostic value |
3 |
|
disparity |
3 |
|
drug resistance |
3 |
|
drug therapy, combination - administration & dosage |
3 |
|
e-selectin - blood |
3 |
|
elderly |
3 |
|
enzyme-linked immunosorbent assay |
3 |
|
epstein-barr virus infections - complications |
3 |
|
fiber |
3 |
|
fluorouracil - analogs & derivatives - therapeutic use |
3 |
|
follow-up studies |
3 |
|
forced expiratory volume |
3 |
|
fruits |
3 |
|
gene frequency |
3 |
|
genetic predisposition to disease |
3 |
|
genetic predisposition to disease - ethnology |
3 |
|
genetic susceptibility |
3 |
|
glutathione transferase - genetics |
3 |
|
glutathione-s-transferases |
3 |
|
great britain - epidemiology |
3 |
|
hospitalization - statistics & numerical data |
3 |
|
idiopathic pulmonary fibrosis |
3 |
|
immunocompromised host |
3 |
|
immunoglobulin |
3 |
|
immunoglobulin a - administration & dosage - therapeutic use |
3 |
|
immunoglobulin m - administration & dosage - therapeutic use |
3 |
|
inflammation |
3 |
|
intercellular adhesion molecule-1 - blood |
3 |
|
leukaemia |
3 |
|
leukemia, myeloid, acute - diagnosis - therapy |
3 |
|
leukemia, promyelocytic, acute - drug therapy - physiopathology |
3 |
|
lung disease burden |
3 |
|
lung diseases - chemically induced - physiopathology |
3 |
|
lung diseases, fungal - diagnosis - epidemiology |
3 |
|
lung function |
3 |
|
lung neoplasms - complications - diagnosis - ethnology |
3 |
|
lung neoplasms - drug therapy - pathology - radiotherapy |
3 |
|
lung neoplasms - enzymology - ethnology - genetics |
3 |
|
lung neoplasms - epidemiology - genetics |
3 |
|
lung neoplasms - etiology |
3 |
|
lung neoplasms - pathology - radiography - virology |
3 |
|
lymphoepithelioma |
3 |
|
lymphoma - etiology |
3 |
|
malignant pleural effusion |
3 |
|
microscopy, electron |
3 |
|
microtubular defects |
3 |
|
microtubules |
3 |
|
microtubules - ultrastructure |
3 |
|
nasal mucosa - cytology - ultrastructure |
3 |
|
neutrophils |
3 |
|
odds ratio |
3 |
|
oncology |
3 |
|
outcome |
3 |
|
oxides - adverse effects |
3 |
|
oxygen |
3 |
|
oxygen inhalation therapy |
3 |
|
p-value |
3 |
|
pathogenesis |
3 |
|
pentaglobin |
3 |
|
pet/ct |
3 |
|
pleural drainage |
3 |
|
pleurodesis |
3 |
|
polymorphisms |
3 |
|
prevalence |
3 |
|
radiotherapy |
3 |
|
respiration, artificial |
3 |
|
respiratory tract diseases - epidemiology - mortality |
3 |
|
review |
3 |
|
risk |
3 |
|
sample size |
3 |
|
sarcoidosis |
3 |
|
sars |
3 |
|
sars virus - isolation & purification |
3 |
|
second primary cancer |
3 |
|
seer |
3 |
|
semirigid pleuroscopy |
3 |
|
severe acute respiratory syndrome - diagnosis - drug therapy |
3 |
|
severe acute respiratory syndrome - physiopathology - radiography - therapy |
3 |
|
severe acute respiratory syndrome - radiography - therapy |
3 |
|
silicosis |
3 |
|
silicosis - complications |
3 |
|
small cell lung cancer |
3 |
|
smoking - adverse effects |
3 |
|
sputum - microbiology |
3 |
|
superoxide dismutase - blood - genetics - metabolism |
3 |
|
thoracentesis |
3 |
|
threshold |
3 |
|
thymidylate synthase |
3 |
|
trial design |
3 |
|
up-regulation |
3 |
|
vascular cell adhesion molecule-1 - blood |
3 |
|
vegetables |
3 |
|
ventricular tachyarrhythmia |
3 |
|
whole grains |
3 |
|
xenograft |
3 |
|
young adult |
3 |
|
aging - pathology - physiology |
2 |
|
apoptosis |
2 |
|
asians |
2 |
|
autophagy |
2 |
|
biochemistry |
2 |
|
biology |
2 |
|
biopsy - methods |
2 |
|
bone marrow transplantation - adverse effects |
2 |
|
breast |
2 |
|
breast neoplasms - physiopathology - radiotherapy - surgery |
2 |
|
bronchial carcinoma |
2 |
|
bronchiectasis - complications - metabolism - microbiology |
2 |
|
bronchiectasis - diagnosis - enzymology |
2 |
|
bronchiectasis - radiography |
2 |
|
bronchiectasis elastase |
2 |
|
bronchiolitis obliterans |
2 |
|
bronchiolitis obliterans - etiology |
2 |
|
bronchiolitis obliterans - pathology - physiopathology |
2 |
|
bronchoalveolar lavage |
2 |
|
bronchoalveolar lavage - methods |
2 |
|
bronchoscopy |
2 |
|
bronchoscopy - methods |
2 |
|
calcium-calmodulin-dependent protein kinases - genetics |
2 |
|
cancer |
2 |
|
carcinoma, bronchogenic - pathology - radiography |
2 |
|
carcinoma, non-small-cell lung - diagnosis - epidemiology - therapy |
2 |
|
carcinoma, non-small-cell lung - genetics |
2 |
|
cell cycle arrest |
2 |
|
cesarean section |
2 |
|
chi-square distribution |
2 |
|
ciliary function |
2 |
|
ciliary motility disorders - complications - etiology |
2 |
|
ciliary motility disorders - drug therapy - pathology - physiopathology |
2 |
|
cisplatin |
2 |
|
copd control |
2 |
|
copd exacerbation |
2 |
|
copd, copd exacerbation |
2 |
|
cyclin-dependent kinase inhibitor p16 - genetics |
2 |
|
diet |
2 |
|
disease control rate |
2 |
|
drainage |
2 |
|
endothelin-1 |
2 |
|
endothelin-1 - metabolism |
2 |
|
environmental exposure |
2 |
|
environmental tobacco smoke |
2 |
|
epidermal growth factor receptor mutation |
2 |
|
epidermal growth factor receptor tyrosine kinase inhibitors |
2 |
|
epstein-barr virus |
2 |
|
etoposide |
2 |
|
family history |
2 |
|
far east - epidemiology |
2 |
|
forced expiratory flow rates - radiation effects |
2 |
|
gene-environment interaction |
2 |
|
graft vs host disease |
2 |
|
graft-versus-host disease |
2 |
|
hematologic neoplasms - complications - therapy |
2 |
|
hematopoietic stem cell transplantation - adverse effects |
2 |
|
immune checkpoint inhibitors |
2 |
|
inflammation mediators - metabolism |
2 |
|
insecticide |
2 |
|
interleukin |
2 |
|
interleukin-1 - analysis |
2 |
|
interleukin-8 - analysis |
2 |
|
interviews as topic |
2 |
|
leukocytes |
2 |
|
leukotriene |
2 |
|
loco-regional |
2 |
|
lung |
2 |
|
lung - pathology |
2 |
|
lung - physiopathology - radiation effects - radiography |
2 |
|
lung neoplasms - diagnosis - epidemiology - therapy |
2 |
|
lung neoplasms - epidemiology - etiology |
2 |
|
lung neoplasms - pathology - radiography |
2 |
|
lung, ct |
2 |
|
mechanism |
2 |
|
mucociliary clearance |
2 |
|
n-acetylcysteine |
2 |
|
nasal mucosa - physiology - ultrastructure |
2 |
|
neutropenia |
2 |
|
never-smokers |
2 |
|
o(6)-methylguanine-dna methyltransferase - genetics |
2 |
|
observer variation |
2 |
|
obstetrical forceps |
2 |
|
occupational exposure |
2 |
|
pancreatic elastase - analysis |
2 |
|
pancreatic elastase - blood |
2 |
|
pneumothorax - therapy |
2 |
|
pneumothorax/surgery |
2 |
|
predictive models |
2 |
|
pregnancy |
2 |
|
pregnancy complications - surgery - therapy |
2 |
|
promoter regions, genetic - genetics |
2 |
|
pseudomonas aeruginosa - isolation & purification |
2 |
|
pseudomonas infections - complications - metabolism |
2 |
|
pulmonary fibrosis - radiography |
2 |
|
questionnaires |
2 |
|
quinazolines - therapeutic use |
2 |
|
radiation injuries - etiology - physiopathology |
2 |
|
radiotherapy effects |
2 |
|
radiotherapy, adjuvant |
2 |
|
rct |
2 |
|
regression analysis |
2 |
|
remission, spontaneous |
2 |
|
resistance |
2 |
|
respiration disorders - etiology - physiopathology |
2 |
|
respiratory function tests - methods |
2 |
|
respiratory mucosa - pathology |
2 |
|
respiratory tract diseases - etiology - physiopathology |
2 |
|
respiratory tract infections - complications |
2 |
|
risk factors |
2 |
|
salvage therapy - methods |
2 |
|
severe acute respiratory syndrome - radiography |
2 |
|
sex factors |
2 |
|
single nucleotide polymorphisms |
2 |
|
smoking |
2 |
|
smoking - epidemiology |
2 |
|
socioeconomic factor |
2 |
|
socioeconomic factors |
2 |
|
sputum - chemistry - cytology - microbiology |
2 |
|
sputum - enzymology |
2 |
|
synergism |
2 |
|
thoracic surgery, video-assisted |
2 |
|
tomography, spiral computed |
2 |
|
total lung capacity - radiation effects |
2 |
|
transplantation conditioning - methods |
2 |
|
transplantation, homologous - adverse effects |
2 |
|
tumor necrosis factor-alpha - analysis |
2 |
|
vital capacity - physiology |
2 |
|
vital capacity - radiation effects |
2 |
|
xenografts |
2 |
|
acquired resistance |
1 |
|
actinomycosis |
1 |
|
actinomycosis - complications - diagnosis - drug therapy |
1 |
|
adenocarcinoma - drug therapy |
1 |
|
algorithm |
1 |
|
alk-positive advanced non–small cell lung cancer |
1 |
|
all cause mortality |
1 |
|
amoxicillin - therapeutic use |
1 |
|
animals |
1 |
|
anti-bacterial agents - therapeutic use |
1 |
|
antimetabolites, antineoplastic - therapeutic use |
1 |
|
antineoplastic agents - pharmacology |
1 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
1 |
|
arsenicals - pharmacology |
1 |
|
asia |
1 |
|
asia pacific |
1 |
|
attitudes |
1 |
|
bct-100 |
1 |
|
bevacizumab |
1 |
|
bone and bones |
1 |
|
breast cancer |
1 |
|
bronchial diseases - complications - diagnosis - drug therapy |
1 |
|
bronchography |
1 |
|
cancer mortality |
1 |
|
cancer screening |
1 |
|
carcinoma - drug therapy - radiography - radiotherapy |
1 |
|
carcinoma, non-small-cell lung - drug therapy - mortality |
1 |
|
carcinoma, non-small-cell lung - enzymology - genetics |
1 |
|
catalase - biosynthesis - genetics |
1 |
|
challenge |
1 |
|
chickens |
1 |
|
cisplatin - administration & dosage |
1 |
|
cisplatin - administration & dosage - adverse effects |
1 |
|
clavulanic acid - therapeutic use |
1 |
|
combination chemotherapy |
1 |
|
contactin 1 |
1 |
|
contactins |
1 |
|
controlled |
1 |
|
crizotinib |
1 |
|
ddpcr |
1 |
|
dendritic cells |
1 |
|
dietary protein sources |
1 |
|
difluoromethylornithine |
1 |
|
discriminant analysis |
1 |
|
disease management |
1 |
|
docetaxel |
1 |
|
drug administration schedule |
1 |
|
e2f1 |
1 |
|
early-stage |
1 |
|
education |
1 |
|
endobronchial |
1 |
|
epidermal growth factor receptor mutations |
1 |
|
fgfr1 inhibitor |
1 |
|
first-line |
1 |
|
fluorouracil - administration & dosage |
1 |
|
foreign bodies - complications - radiography |
1 |
|
foreign body |
1 |
|
g1 cell cycle arrest |
1 |
|
galectins |
1 |
|
glutathione |
1 |
|
hydrogen peroxide |
1 |
|
immune checkpoint antibodies |
1 |
|
immune checkpoint blockade |
1 |
|
immuno-oncology therapy |
1 |
|
immunotherapy |
1 |
|
infusions, intravenous |
1 |
|
inhaler techniques |
1 |
|
interleukin-9 |
1 |
|
intracellular |
1 |
|
leucovorin - administration & dosage |
1 |
|
lung carcinoma |
1 |
|
lung neoplasms |
1 |
|
lung neoplasms - drug therapy - mortality |
1 |
|
lung neoplasms - drug therapy - radiography - radiotherapy |
1 |
|
lung neoplasms - enzymology - genetics |
1 |
|
malignant pleural mesothelioma |
1 |
|
mesothelioma |
1 |
|
meta-analysis |
1 |
|
mhc-i |
1 |
|
mitochondrial membrane depolarization |
1 |
|
mutant copy number |
1 |
|
neoplasms |
1 |
|
neural cell adhesion molecule l1 |
1 |
|
non-small cell |
1 |
|
non-small cell lung carcinoma |
1 |
|
ornithine decarboxylase |
1 |
|
ornithine decarboxylase 1 inhibitor |
1 |
|
oxidative stress |
1 |
|
oxides - pharmacology |
1 |
|
paclitaxel - administration & dosage - adverse effects - analogs & derivatives |
1 |
|
patient burden |
1 |
|
pegylated arginase |
1 |
|
pegylated arginase (bct-100) |
1 |
|
penicillins - therapeutic use |
1 |
|
perception |
1 |
|
peripheral pulmonary nodules |
1 |
|
phase iii |
1 |
|
physician-patient communications |
1 |
|
programmed cell death protein 1 |
1 |
|
programmed death ligand 1 |
1 |
|
proteasome degradation system |
1 |
|
rna, messenger - biosynthesis - genetics |
1 |
|
secretory |
1 |
|
solitary pulmonary nodules |
1 |
|
spermidine |
1 |
|
squamous cell lung carcinoma |
1 |
|
staging |
1 |
|
superoxide dismutase - biosynthesis - genetics |
1 |
|
survival rate |
1 |
|
symptoms |
1 |
|
targeted treatment |
1 |
|
taxoids |
1 |
|
thioredoxin 1 |
1 |
|
thymidylate synthase - genetics |
1 |
|
thymidylate synthase - metabolism |
1 |
|
thymoquinone |
1 |
|
transcription factor e2f1 |
1 |
|
tumor microenvironment |
1 |
|
tumor size |
1 |
|
tyrosine kinase inhibitors |
1 |
|
xenograft models |
1 |
